

Arch hybrid procedures: are they effective and durable?



Imperial College
London


Colin D Bicknell

Clinical Senior Lecturer and Consultant Vascular Surgeon
Imperial College London, UK



- Medtronic: Consultancy, Speakers fees, travel and conference fees
- Orzone: Institutional level capital funding and training fees
- Bolton Medical: Consultancy, speakers fees, travel and conference fees
- Gore: Travel and conference fees




ARCH HYBRID SURGERY



ARCH HYBRID PROCEDURES




Variable (N=55)		
Median age		67 (38-88)
Male sex		36 (65.5%)
ASA Grade	1	0
	2	7 (12.8%)
	3	35 (63.6%)
	4	13 (23.6%)
Renal impairment (eGFR <60ml/min/1.73m ²)		14 (25.5%)
Previous aortic repair/surgery		18 (32.7%)
Connective tissue disorder		3 (5.5%)
Emergency (<24hrs from presentation)		7 (12.7%)
Symptomatic		28 (51.0%)
Aortic Pathology	Aortic aneurysm	40 (72.7%)
	Acute Type B dissection	10 (18.2%)
	Acute Type A dissection	1 (1.8%)
	Other	4 (7.3%)
Mean number stents		2.5 (1-9)
Spinal drain		40 (72.7%)
Ishimaru landing zone (N=53)	0	14 (26.4%)
	1	19 (35.9%)
	2	20 (37.7%)





- 32/55 (58.2%) performed as single stage procedures
- 2.52 (1-9) aortic stents/patient
- 40/55 (72.7%) spinal drain
- Primary technical success, was achieved in 52/55 (94.5%) of cases
 - Aneurysm rupture between stages
 - Stent graft deployment failure (access)
 - Type 1a




- Mortality (30D) 3.6% (2/55).
 - Elective 2.1% (1/48)
 - Emergency 14.3% (1/7)
- In Hospital Mortality 9.1% (5/55)
- 8 complications related to extra-anatomical bypass grafts
- 4 Further interventions



- Stroke rate
 - 6/48 elective/urgent
 - 2/7 emergency
- Early endoleak rate
 - 1a – treated with chimney and extension
 - 1b – treated with extension
 - Two type 2, planned subclavian occlusion
 - Two type 2, under surveillance

FIVE YEAR SURVIVAL



Overall mean follow-up


- 74.6 months (95% CI 57.5-91.7).

Cumulative survival

- 70% at 1 year
- 68% at 2 years
- 57% at 3 years.

At risk patients 55 36 25 23 11 8

Cumulative re-intervention free survival comparing
proximal landing zone vs. other re-intervention vs.
all aortic re-intervention



At risk patients 55 36 25 23 11 8

Bypass patency rate of 98.7%
(78/79).

Long term reintervention
2 type 1a endoleaks

6 type 1b endoleaks
6 type 2 endoleaks
2 type 3 endoleaks

SCALLOPED TECHNOLOGY



Endovascular treatment of thoracic aortic aneurysms
with a short proximal landing zone using scalloped
endografts

Ali Alsafi, MBBS, BSc (Hons),^a Colin D. Bicknell, MD, FRCS,^{b,c} Nung Rudarakanchana, PhD, MRCS,^{b,c}
Elika Kashaf, FRCS, MRCS,^a Richard G. Gibbs, MD, FRCS,^{b,c} Nicholas J. Cheshire, MD, FRCS,^{b,c}
Michael P. Jenkins, BSc, MS, FRCS, FRCS (Gen Surg), FEBVS,^{b,c} and Mohamad Hamady, FRCS, EBIR,^{a,b,c}
London, United Kingdom

- Bolton double arch branch experience
 - Growing
 - Technical success
 - One type A dissection and one CVA
 - No re-intervention in the short term

- Other devices on the markets all with short term follow up





COOK inner branched device
(38 patients)

- Early mortality and neurologic events 17.9% after learning curve

12 month follow up for 33 survivors

- Further 12.1% mortality, 1 stroke
- Endoleaks in 9.1%, only one type 1
- 1 branch obstruction, 1 open conversion



Subsequent series

- No death at 30 days
- Major stroke 7.4%, minor 3.7%
- Early intervention 14.8%
- One death and two re-interventions over a year

The hybrid technique has been criticized for disappointing results in the short term

- Acceptable mortality and morbidity in the short term in elective patients
- Long term re-intervention rate excellent

A totally endovascular approach is promising

- Short term follow up – acceptable complication rate and re-intervention rate
- Stroke for total arch replacements remains an issue

These data are a benchmark for totally endovascular repair to improve on

- In the short term we need to understand the results in those less anatomically suitable for arch branch devices and with disease in arch
- In the long term we need to understand the results over extended follow up